36 Chapter 2 Table 3: Study characteristics and baseline patient characteristics categorized by type of radiotherapy RT type Authors and year of publication Study type Radiation schedule N Sex (M:F) Median age in years (range or N of patients) KPS (N of patients) Number of BMs (N of patients) Median total volume of BMs in cc Median overall survival in months Primary tumor location (N of patients) WBRT Mehta et al., 2003 18,36–38 Phase III RCT WBRT 30 Gy/10 fr 208 90:118 58 (N.A.) 70 (43) 80 (55) 90 (77) 100 (33) 1 (41) 2-3 (69) 4-6 (41) >6 (53) N.A. 4.9 Lung (128) Breast (42) Other (38) Gondi et al., 2014 26,27,33 Phase II trial HA-WBRT 30 Gy/10 fr 100 N.A. 61 (28-83) 70 (19) 80 (17) 90 (39) 100: 25 N.A. 6.7 6.8 Lung (56) Breast (15) Other (29) Saito et al., 2016 28 Prospective trial WBRT 30 Gy/10 fr 18 21:13 65.5 (39-86) ≤70 (22) ≥80 (12) N.A. N.A. N.A. Lung (20) Breast (7) Other (7) WBRT 35 Gy/14 fr 16 Deng et al., 2017 35 Retrospective trial WBRT 30 Gy/10 fr 109 67:42 ≤60 (38) >60 (71) N.A. ≤3 (32) >3 (77) N.A. 7.3 Lung (109) Cheng et al., 2018 46 Prospective trial WBRT 40 Gy/20 fr 81 48:33 <65 (39) ≥65 (42) ≥80 (81) <3 (54) ≥3 (23) N.A. 7.5 Lung (49) Other (32) Zhan et al., 2018 39 RCT WBRT 30 Gy/15 fr 117 68:49 ≤60 (51) >60 (66) <70 (85) ≥70 (32) ≤2 (94) >2 (23) N.A. 6.5 N.A. Zhu et al., 2018 40 Retrospective trial WBRT 40 Gy/20 fr 33 18:15 ≤61 (14) >61 (19) N.A. ≥4 (33) N.A. 7.5 Lung (33) Westover et al., 2020 41 Phase II trial HA-WBRT + SIB 20 Gy/10 fr + 40 Gy/10 fr 49 24:25 60 (54-65) ≥70 (49) 1-3 (19) 4-6 (20) 7-8 (10) 0.8 9.0 Lung (39) Breast (5) Other (5) Onodera et al., 2014 25 Nonrandomized pilot study WBRT 35 Gy/14 fr 20 11:9 62.6 (N.A.) 70 (1) 80 (2) 90 (17) <3 (6) ≥3 (14) 6.7 N.A. Lung (17) Breast (1) Other (2)
RkJQdWJsaXNoZXIy MTk4NDMw